XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2015
Filed with the SEC on May 27, 2015 and accepted by EDGAR at May 27, 2015, 15:23 ET.
Management's discussion and analysis
As filed, 19,220 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of different diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization technologies or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While primarily focused on bringing our lead product candidate to market, we have also developed a proprietary True Human™ monoclonal antibody discovery platform and manufacturing system.
We have never been profitable and, as of March 31, 2015, we had an accumulated deficit of $101.3 million. We had net losses of $8.1 and $4.5 million for three months ended March 31, 2015 and March 31, 2014, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and begin to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. On April 17, 2015, The Company closed its initial public offering of 4,000,000 shares of its common stock at a price of $19.00 per share for a total offering amount of $76,000,000, before the underwriting discounts and commissions and other company expenses. Net proceeds to the Company totaled approximately $70.9 million after deducting underwriting discounts and commissions of $3.8 million and other offering expenses of approximately $1.3 million.
Revenues
To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, Xilonix™, or any other product candidate we may advance in the future.
Research and Development Expenses
Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.
Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2015, we have recorded total research and development expenses, including share-based compensation, of $76.8 million. Our total research and development expenses for the three months ended March 31, 2015 and 2014 were $6.8 million and $2.3 million, respectively. Share-based compensation accounted for $0.4 million and $0.1 million for the three months ended March 31, 2015 and 2014, respectively.
Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2015 and 2014 were 83% and 52%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2015 and 2014, were 91% and 83%, respectively.
We expect our clinical costs to be substantial and to increase as we advance Xilonix™ through Phase III clinical trials in Europe and the U.S. and research and development costs to increase as we move other drug candidates into preclinical testing and clinical trials. Based on the results of our preclinical studies, we expect to selectively advance some drug candidates into clinical trials. We anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential.
During 2015, we intend to continue our Phase II study in Pyoderma Gangrenosum, or PG. Assuming that we continue to see positive results in the Phase II study, we may seek breakthrough designation from the FDA. After evaluation of the Phase II data, we will also determine our interest in conducting a pivotal Phase III study in this indication. As this is an orphan condition, with a relatively small incidence (estimated at less than 3,000 patients) in the United States, a pivotal study would likely need to be conducted in both the United States and Europe.
A Phase I/II randomized, placebo controlled, dose escalation study for our antibody therapy for S. aureus infections is planned in 2015. We filed an IND in December 2014 for the study, which is currently on clinical hold, while at the request of the FDA, we complete an animal toxicology study. The results of the toxicology study were submitted to the FDA in March 2015 and we are waiting for notification from the FDA to continue our clinical study.
Due to the fact that our drug candidates are in the early stage of development, we cannot estimate anticipated completion dates and when we might receive material net cash inflows from our research and development projects.
General and Administrative Expenses
General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2015 and 2014 were $1.4 million and $2.2 million, respectively. Share-based compensation accounted for $0.8 million and $1.7 million for the three months ended March 31, 2015 and 2014, respectively.
Critical Accounting Policies
Our Management’s Discussion and Analysis of our Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States, or US GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.
We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in the notes to our financial statements appearing in this prospectus, we believe that the following accounting policies are the most critical to understanding and evaluating our reported financial results.
Stock-Based Compensation
Stock-based awards are measured at fair value at each grant date. We recognize stock-based compensation expenses ratably over the requisite service period of the option award.
Determination of the Fair Value of Stock-Based Compensation Grants
The determination of the fair value of stock-based compensation arrangements is affected by a number of variables, including estimates of the fair value of our common stock, expected stock price volatility, risk-free interest rate and the expected life of the award. We value stock options using the Black-Scholes option-pricing model, which was developed for use in estimating the fair value of traded options that are fully transferable and have no vesting restrictions. Black-Scholes and other option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. If we made different assumptions, our stock-based compensation expenses, net loss, and net loss per common share could be significantly different. During all of the periods presented, we issued common stock for cash consideration to new investors. We believe that such transactions represent the best evidence of fair value of our common stock. Therefore, we used the sales price of our common stock during these periods as the fair value of our common stock.
The following summarizes the assumptions used for estimating the fair value of stock options granted during the periods indicated:
| Three Months Ended March 31, 2015 | 2014 | |
|---|---|---|
| Weighted-average grant date fair value per share | $9.56 | $7.14 |
| Expected volatility | 68% | 70% |
| Risk-free interest rate | 1.39% - 2.12% | 0.69% - 2.73% |
| Expected life (in years) | 5 - 10 | 3 - 10 |
| Dividend yield | – | – |
We have assumed no dividend yield because we do not expect to pay dividends in the foreseeable future, which is consistent with our past practice. The risk-free interest rate assumption is based on observed interest rates for U.S. Treasury securities with maturities consistent with the expected life of our stock options. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method when the stock option includes “plain vanilla” terms. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the agreement term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options. For stock options that did not include “plain vanilla” terms we used the contractual life of the stock option as the expected life. Such stock options consisted primarily of options issued to our board of directors that were immediately vested at issuance. Expected volatility is based on historical volatilities for publicly traded stock of comparable companies over the estimated expected life of the stock options.
We based our estimate of pre-vesting forfeitures, or forfeiture rate, on historical forfeiture rates. We apply the estimated forfeiture rate to the total estimated fair value of the awards, as derived from the Black-Scholes model, to compute the stock-based compensation expenses, net of pre-vesting forfeitures, to be recognized in our consolidated statements of operations.
Results of Operations
Revenue
We did not record any revenue during the three months ended March 31, 2015 and 2014.
Expenses
Research and Development
Research and Development costs are summarized as follows (in thousands):
| Three Months Ended March 31, 2015 | 2014 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Labor | $1,430 | $905 | $526 | 58% |
| Consumables | 1,335 | 465 | 870 | 187% |
| Clinical trials and sponsored research | 2,689 | 324 | 2,365 | 730% |
| Stock-based compensation | 456 | 73 | 383 | 525% |
| Other | 874 | 583 | 291 | 50% |
| Total | $6,784 | $2,350 | $4,435 | 189% |
We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.
Research and development expenses increased by $4.4 million to $6.8 million for the three months ended March 31, 2015, compared to $2.4 million for the three months ended March 31, 2014. This increase was principally due to a $2.4 million increase in clinical trial activities mainly in Europe. The costs for research and development used consumables increased due to the increase of research and development as well as manufacturing processing development activities. Labor costs also increased due to the increase of current employee’s salaries and increase in the size of the workforce. Stock-based compensation increased due to the stock options awarded in 2014 and the continuing vesting of such awards.
General and Administrative
General and administrative costs are summarized as follows (in thousands):
| Three Months Ended March 31, 2015 | 2014 | Increase (Decrease) | % Increase (Decrease) | |
|---|---|---|---|---|
| Labor | $199 | $153 | $46 | 30% |
| Patent filing expense | 227 | 143 | 84 | 59% |
| Stock-based compensation | 767 | 1,768 | (1,001) | (57%) |
| Professional fees | 132 | 31 | 101 | 326% |
| Other | 96 | 59 | 37 | 63% |
| $1,421 | $2,154 | $(733) | (34%) |
General and administrative expense decreased by $0.7 million to $1.4 million for the three months ended March 31, 2015, compared to $2.2 million for the three months ended March 31, 2014. The decrease was primarily related to decreases in stock–based compensation expenses of $1.0 million, due to the grant of stock options to consultants and board members in 2014 that were fully vested.
Liquidity and Capital Resources
Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.
Since our inception on March 22, 2005 through March 31, 2015, we have funded our operations principally through the private placement of equity securities, which have provided aggregate cash proceeds of approximately $132.0 million. The following table summarizes our sources and uses of cash (in thousands):
| Net cash (used in) provided by: | Three Months Ended March 31, 2015 | 2014 |
|---|---|---|
| Operating activities | $(6,531) | $(2,339) |
| Investing activities | (571) | (58) |
| Financing activities | 2,107 | 11,605 |
| Net change in cash and cash equivalents excluding foreign exchange rate effect | $(4,995) | $9,208 |
During the three months ended March 31, 2015 and 2014, our operating activities used net cash of $6.5 million and $2.3 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was due to increases in clinical trial activities in Europe.
During the three months ended March 31, 2015 and 2014, our investing activities used net cash of $0.6 million and $0.1 million, respectively. We spent approximately $315 thousand more on the construction of new facilities during the three months ended March 31, 2015 compared to the three months ended March 31, 2014. We also spent $126 thousand more on purchases of research and development equipment during the three months ended March 31, 2015 compared to the three months ended March 31, 2014.
During the three months ended March 31, 2015 and 2014, our financing activities provided net cash proceeds of $2.1 million and $11.6 million, respectively. During the three months ended March 31,2015, we received requests from investors for the exercise of warrants to purchase a total of 164,999 shares of common stock at $15.00 per share for a total of approximately $2.4 million in net proceeds, which is compared to a total of 1,195,000 shares of common stock issued at $10.00 per share for a total of approximately $11.6 million in net proceeds for the three months ended March 31, 2014. During the three months ended March 31, 2015, we incurred deferred offering costs of $712 thousand, which consist of direct incremental legal, accounting and other professional service fees related to our IPO. In January 2015, we received the previously outstanding subscription receivable in the amount of $410 thousand.
We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the FDA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2015, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $52.2 million.
On April 14, 2015, our registration statement on Form S-1 (File No. 333-201813) was declared effective by the Securities and Exchange Commission for our initial public offering pursuant to which we sold an aggregate of 4,000,000 shares of our common stock at a price to the public of $19.00 per share. The offering commenced as of April 14, 2015 and did not terminate before all of the securities registered in the registration statement were sold. On April 17, 2015, we closed the sale of such shares, resulting in net proceeds to us of approximately $70.9 million after deducting underwriting discounts and commissions of $3.8 million and other offering expenses of approximately $1.3 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the Securities and Exchange Commission on April 16, 2015 pursuant to Rule 424(b).
Contractual Obligations and Commitments
On January 12, 2008, we entered a lease agreement to lease our facility in Austin, Texas. On September 15, 2010, we entered into a second lease agreement to lease additional space in Austin, Texas. On March 20, 2014, we extended the lease for an additional 21 months on the same terms and rental rates as the current lease. Rent expense was $105 thousand and $101 thousand for the three months ended March 31, 2015 and 2014, respectively. On February 28, 2015, we extended the lease for another 4 years. The future minimum lease payments are as follows as of March 31, 2015 (in thousands):
| Contractual Obligations | Total | Less than 1 Year | 1 - 3 Years | 3 - 5 Years | More than 5 Years |
|---|---|---|---|---|---|
| Operating facility leases | $1,784 | $437 | $914 | $433 | $— |
| Total contractual obligations | $1,784 | $437 | $914 | $433 | $— |
Off-Balance Sheet Arrangements
Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.
Market risk
As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.
Controls and procedures
As filed, 1,864 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management's Evaluation of our Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.
Changes in Internal Control
There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Risk factors
As filed, 125 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in the risk factors previously disclosed in our final prospectus filed on April 16, 2015.
Source: SEC EDGAR, the filing index for accession 0001171843-15-003134. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.